Endocrinology General Medicine Strong — NICE CG189, WHO
BMI + Metabolic Risk Assessment
Combined BMI and waist circumference assessment for metabolic risk classification.
References
- NICE CG189. Obesity: identification, assessment and management. 2014 (updated 2023).
- WHO. Obesity and overweight. Fact sheet. 2024.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Trimetazidine · Metabolic Anti-Anginal
- L-Carnitine · Antidote / Metabolic Agent
- Semaglutide · GLP-1 Receptor Agonist
- Liraglutide · GLP-1 Receptor Agonist
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
- Pituitary Apoplexy · ENEA 2011 / Pituitary Society
- Hypercalcaemia Management · NICE / Endocrine Society
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.